Enthera Pharmaceuticals
Focus: Enthera Pharmaceuticals is a public Italian biotech company founded in 2016 specializing in IGFBP3 inhibitors using monoclonal antibody and fusion protein platforms targeting neurology indications. The company operates on a narrow revenue base concentrated in legacy assets.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Enthera Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Enthera Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
1 in 5yr
SIRTURO
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$3MDeclining
LOE Approaching
Help build intelligence for Enthera Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.